NCT03838042 2024-02-07INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory MalignanciesUniversity Hospital HeidelbergPhase 1/2 Recruiting91 enrolled
NCT02780804 2023-10-17Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid TumorsNational Cancer Institute (NCI)Phase 1 Completed21 enrolled 15 charts